Cynata Therapeutics Ltd

CYP

Company Profile

  • Business description

    Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.

  • Contact

    100 Cubitt Street
    Level 3
    CremorneVIC3121
    AUS

    T: +61 370676940

    https://www.cynata.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    Employees

    2

Stocks News & Analysis

stocks

The best AI stocks to buy now

Artificial intelligence stocks maintain their allure, thanks to industry momentum and appealing valuations.
stocks

ASX share undervalued despite solid growth

First-quarter performance exceeds expectations.
stocks

Chart of the Week: 3 undervalued US tech shares

Our US analysts’ top tech opportunities.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,871.3048.100.55%
CAC 407,729.6939.52-0.51%
DAX 4024,806.97297.39-1.18%
Dow JONES (US)51,231.6451.770.10%
FTSE 10010,441.6016.90-0.16%
HKSE24,079.30293.511.23%
NASDAQ27,193.34345.35-1.25%
Nikkei 22568,512.30529.81-0.77%
NZX 50 Index13,720.4428.590.21%
S&P 5007,765.3636.41-0.47%
S&P/ASX 2008,708.7047.800.55%
SSE Composite Index3,764.3547.55-1.25%

Market Movers